HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir
about
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South AfricaHigh prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South AfricaHIV-1 drug resistance and resistance testing.HIV-1 genetic variation and drug resistance development.Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western IndiaResistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.Recent findings on the mechanisms involved in tenofovir resistance.COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.Analysis of a local HIV-1 epidemic in portugal highlights established transmission of non-B and non-G subtypesTreatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western KenyaBasis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug ResistanceAn association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.
P2860
Q28535483-BE85EDB5-8C3A-4A75-B4F4-EB5DE4DC5EA1Q28543358-438608D4-76D0-4F5A-8191-2188CC7D5BC6Q30245693-D92B7646-8B18-451F-AB7A-A2AEAA014096Q30354857-5FB58309-9877-45B4-81F5-21235F7248DCQ33595427-8C927B8E-AD1D-4F39-9ABA-A92E53810901Q33714130-97FE0182-602C-4727-9562-807684DCF6BDQ33831709-42F4AA53-9285-4198-859E-3063B9EACA11Q34312943-1B5741ED-7AE8-4102-B1C9-130AE17B69E2Q35455551-CD97167C-C4CB-471C-A8C9-7C52BF460003Q36940983-03F5F014-CA87-4868-8C18-91F64CAAC1B7Q37263786-9FB113FA-F0E4-4F21-B0DE-8CFAC6247A59Q37365060-5C4CFC37-0D9D-4938-A4A4-E84F0CD103DEQ39360243-7663D2C8-FC1E-49F6-BE99-B481A5258ECCQ41293200-71F626F2-7DF5-41EE-BF38-E1BDA13DC9C5Q42380140-3573597A-9C74-4004-9F18-37F728B332B1Q55340159-B35663BC-679F-4894-9838-14D83703F8D1
P2860
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
HIV-1 subtype is an independen ...... al therapy including tenofovir
@ast
HIV-1 subtype is an independen ...... al therapy including tenofovir
@en
type
label
HIV-1 subtype is an independen ...... al therapy including tenofovir
@ast
HIV-1 subtype is an independen ...... al therapy including tenofovir
@en
prefLabel
HIV-1 subtype is an independen ...... al therapy including tenofovir
@ast
HIV-1 subtype is an independen ...... al therapy including tenofovir
@en
P2093
P2860
P50
P356
P1476
HIV-1 subtype is an independen ...... al therapy including tenofovir
@en
P2093
A B Abecasis
A Sönnerborg
E Schülter
J Vercauteren
Z Grossman
P2860
P304
P356
10.1128/AAC.01668-12
P407
P577
2012-11-26T00:00:00Z